Top 10 stocks for November
What are the top traded stocks in November?
According to global multi-asset investment platform eToro, Australian retail investors piled into stocks of companies that are expected to perform well in the year to come.
Nio Inc (NYSE: NIO) remains as the top most invested stock by Australian investors, for the second consecutive month in a row.
Palantir Technologies’ (NYSE: PLTR) recent earnings report excites investors, as the company shows clear signs that the business is looking to grow throughout 2021.
Pfizer (NYSE: PFE) has skyrocketed into the portfolios of many Australian investors in November, as the company announces its vaccine is 95 per cent effective.
The top 10 stocks are:
Here’s market analyst at eToro Josh Gilbert’s assessment ...
Nio has seen a huge gain of 145 per cent in trading activity in November, as investors look to pile into the stock after what can only be described as ‘FOMO’ from its 1,000 per cent price increase this year.
The EV sector has had a phenomenal run in 2020, despite a market sell off in early March. Nio Inc has outperformed Tesla so far this year, which is surprising as a year ago many investors wouldn’t have thought twice about the Chinese automobile manufacturer.
The recent news that Tesla would be added into the S&P 500 later this month has sent the share price racing in November, gaining more than 40 per cent. The move means that the hedge funds tied to the S&P 500 will have to buy billions of dollars’ worth of shares in the company to add to their portfolios, which investors are seemingly pricing in.
Palantir’s increase in revenue guidance has excited investors, as they start to clue in around the potential behind the stock. Its recently released first earnings report was positive, and showed clear signs that the business is looking to grow throughout 2021. The company has also worked closely with the US government over the pandemic period, which puts them in a great position to continue to work with government agencies, such as the US Army and intelligence services.
Alibaba’s share price tumbled in November, falling as much as 15 per cent. With expectations that the eCommerce industry will continue to accelerate in 2021, investors have seen this as a prime opportunity to purchase shares in Alibaba. Alibaba also recently recorded around $75 billion in sales from The Singles Day event, with $5 billion of these sales coming directly out of US. This shows a continued resilience from Alibaba to grow outside of the Chinese market.
Pfizer, the front runner behind the coronavirus vaccine, has skyrocketed into the portfolios of many Australian eToro investors in November, with a 1076 per cent increase in trading activity. Pfizer’s stock gained around 11 per cent in November, as the company announced the vaccine they had produced was 95 per cent effective.
With an impending decision from the US FDA to approve the drug, the mass scale in which the vaccine would be purchased will provide Pfizer with a steady income stream in the short term. The vaccine has also been approved for emergency use by the UK government, with more than 40 million doses of the vaccine purchased. This is set to pave the way for mass approval around the globe.”
Short-term positions in small, early stage ASX companies,
with high potential and near term price catalysts.
Focusing on resource exploration, early-stage tech, and biotech.
Exceptional opportunities across a broad range of
early-stage growth sectors with strong management.
Seeking 1,000% plus returns across medium to long-term holds.
Longer-term positions in a variety of sectors.
Seeking strong management where traction is established and have entered into a growth phase.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.